BC
IOVA icon

Broadfin Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Broadfin Capital’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		$14.8M Sell
533,301
-597,800
-53% -$13.6M 1.98% 16
2019
Q3 		$20.6M Sell
1,131,101
-428,198
-27% -$9.47M 3.81% 6
2019
Q2 		$38.2M Sell
1,559,299
-2,769,004
-64% -$41.7M 8.32% 1
2019
Q1 		$41.2M Sell
4,328,303
-1,622,850
-27% -$15.8M 8.5% 1
2018
Q4 		$52.7M Buy
5,951,153
+1,056,792
+22% +$10.2M 6.93% 2
2018
Q3 		$55.1M Buy
4,894,361
+747,756
+18% +$10.6M 8.1% 2
2018
Q2 		$53.1M Buy
4,146,605
+3,233,618
+354% +$47.3M 8.36% 1
2018
Q1 		$15.4M Sell
912,987
-1,427,624
-61% -$21.6M 2.4% 17
2017
Q4 		$18.7M Sell
2,340,611
-147,011
-6% -$1.18M 3.06% 15
2017
Q3 		$19.3M Buy
2,487,622
+211,263
+9% +$1.34M 2.85% 14
2017
Q2 		$16.7M Sell
2,276,359
-232,700
-9% -$1.48M 2.03% 16
2017
Q1 		$18.7M Sell
2,509,059
-129,200
-5% -$947K 2.26% 16
2016
Q4 		$18.3M Hold
2,638,259
– – 2.04% 14
2016
Q3 		$21.7M Sell
2,638,259
-532,500
-17% -$4.5M 1.95% 13
2016
Q2 		$25.7M Buy
3,170,759
+1,065,240
+51% +$6.69M 2.5% 10
2016
Q1 		$10.7M Hold
2,105,519
– – 1.03% 27
2015
Q4 		$16.3M Hold
2,105,519
– – 1% 25
2015
Q3 		$12.1M Buy
2,105,519
+293,100
+16% +$2.28M 0.67% 36
2015
Q2 		$16.6M Buy
1,812,419
+750,000
+71% +$8.37M 0.89% 32
2015
Q1 		$12.9M Buy
+1,062,419
New +$12M 1% 24

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Broadfin Capital's IOVA Position: Q4 2019 in Review

Broadfin Capital reduced its Iovance Biotherapeutics (IOVA) stake by 53% in Q4 2019, selling an estimated $13.6M and leaving 533,301 shares worth $14.8M. The position accounts for 1.98% of the portfolio, ranked #16.

Broadfin Capital first reported a position in IOVA in Q1 2015 and has held it in 20 quarters since. The position peaked at $55.1M in Q3 2018. 200 funds tracked by Wall St. Rank hold IOVA as of Q4 2019.

  • Broadfin Capital held 533,301 shares of Iovance Biotherapeutics worth $14.8M as of Q4 2019.
  • Broadfin Capital sold 597,800 Iovance Biotherapeutics shares in Q4 2019, an estimated $13.6M.
  • Iovance Biotherapeutics made up 1.98% of Broadfin Capital's portfolio in Q4 2019, its #16 holding.
  • Broadfin Capital first reported a position in Iovance Biotherapeutics in Q1 2015 and has held it in 20 quarters since.
  • Broadfin Capital's Iovance Biotherapeutics position peaked at $55.1M in Q3 2018.
  • 200 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.